Mission
Committed to Society, Environment, and Good Health
We consolidate the necessity on the development of rare diseases, to make the impossible possible.
Professional
Develop Innovative Drugs with Expert and Pioneer Technology
We hold tight bonds with international KOL, medical corporates, and co-developer. We cultivate various meaningful pipelines to provide better treatment for the world.
Vision
Overcome Barriers with Patients
We work on partnering, transactions, licensing, and authorizations, only to bring patients to brighter solutions.
Founder, Chairman / CEO, Sinphar Group
Chih Wen Lee
- BA, School of Pharmacy, Kaoshiung Medical University
Mr.Lee founded Sinphar Pharmaceutical Co., Ltd. in 1977. he is currently an active member of the pharmaceutical industry and is well respected. Mr.Lee is the director of I-Lan Youngsun Education Foundation, Canadian Aging and Cancer Foundation, and Taiwan Cancer Foundation. Also, he is the council member of Society of Chinese Bioscientists in America, Pharmaceutical Division. He was the former president of Chinese-Canadian Academic and Professional Association, and the co-chairman of Pharmaceutical Market Conference organized by International Chinese Biotechnology Association. Mr. Lee also participates in Taiwanese National Development Assembly Forums and is a committeeman of Drug reviewing Committee of National Science Council.
Management Team
Deputy Chairman
Yita Lee, Ph.D.
- Ph.D. Michael Smith Laboratories & Department of Chemical and Biological Engineering, University of British Columbia
- M.Eng. Department of Chemical Engineering, McGill University
Dr. Yita Lee has become the Deputy Chairman of SynCoreBio Co., Ltd. in 2014. Dr Lee is with Sinphar Group as the Chief Scientific Officer and as the President of CanCap Pharmaceutical Ltd., Canada, in charge of the plant manufacturing of pharmaceutical and nutraceutical soft-gelatin products. He also serves as the Board member in Taiwan Bio Industry Organization since 2008 and the director of Mont Jade Science and Technology Association, Canada, since 2006.
General Manager
Muh-Hwan Su, Ph.D.
- Ph.D. Pharmaceutics and Pharmaceutical Chemistry, University of Utah, U.S.A
- M.S. Pharmaceutics and Pharmaceutical Chemistry, The Ohio State University, U.S.A
- B.S. Pharmacy, National Defense Medical Center
Dr. Su has been the General Manager of SynCore Biotechnology Co., Ltd. since June 3rd, 2013. Prior to that, he had worked as the CSO and COO in Sinphar Group since 2001. Before joining the Sinphar Group, Dr. Su had been an Associate Professor in the school of Pharmacy, National Defense Medical Center. Dr. Su has expertise and immense experience in the R&D of pharmaceutical dosage forms especially transdermal delivery system of new drugs, as well as evaluation, strategic innovation, planning and partnership. Dr. Su has successfully led the team to achieve phase I, II, and phase III projects of investigational new drug (IND) approved by US FDA, TFDA, CFDA and Belgium authority.
Director of Oncology
Hui-Hung Wang
- Master of Management, University of South Australia, Australia
- Bachelor of Science, Pharmacy, Taipei Medical University
Prior to joining SynCoreBio Co., Ltd., Mr. Wang had worked in Sinphar Pharmaceuticals for over 10 years, held positions in the director of academic and assistant general manager of chairman’s office. Currently, he is in charge of the cancer drugs project, including SB01, SB02 and SB05.
